EGFR and non-small cell lung carcinoma: Consequently, various combination approaches (Table 3) have been investigated with the dual objectives of achieving additive or synergistic therapeutic effects and delaying the emergence of resistance, with the ultimate aim of optimizing patient outcomes in the context of EGFR-mutant NSCLC.